Abstract
Edwards Lifesciences will report its fourth-quarter 2025 results on February 10, 2026 Post Market, and consensus points to year-over-year revenue growth with improving profitability metrics, as investors weigh momentum in transcatheter therapies and margin discipline.
Market Forecast
For the current quarter, forecasts indicate Edwards Lifesciences’ revenue of $1.55 billion with year-over-year growth of 13.90%, EBIT of $396.80 million with year-over-year growth of 12.99%, and adjusted EPS of $0.62 with year-over-year growth of 11.51%. Gross profit margin and net profit margin guidance were not explicitly provided in the forecast dataset; however, the company’s prior quarter margin profile provides a reference point for expectations. The main business, transcatheter heart valve therapies, is expected to sustain robust demand as procedure volumes expand; surgical structural heart should continue to benefit from product refreshes and mix improvement. The most promising segment is transcatheter heart valve therapies, which contributed $1.30 billion last quarter and is tracking double-digit growth year over year.
Last Quarter Review
In the previous quarter, Edwards Lifesciences reported revenue of $1.55 billion, a gross profit margin of 77.77%, GAAP net profit attributable to the parent company of $291.00 million with quarter-on-quarter change of -12.64%, a net profit margin of 18.74%, and adjusted EPS of $0.67 with year-over-year performance noted in the forecast comparison set. A notable highlight was robust operating performance relative to expectations, with EBIT of $426.80 million exceeding prior estimates and supported by favorable mix and operating leverage. Main business highlights included transcatheter heart valve therapies revenue of $1.30 billion and surgical heart valve therapy revenue of $258.00 million, with transcatheter therapies demonstrating the larger growth contribution.
Current Quarter Outlook
Transcatheter Heart Valve Therapies
Transcatheter heart valve therapies remain the core growth engine this quarter, driven by ongoing adoption across geographies and continued expansion of eligible patient cohorts. Procedure volumes are poised to benefit from stable hospital capacity and refined patient selection criteria, supporting sustained double-digit revenue growth. Pricing appears stable, and mix shift toward premium devices can enhance average selling prices, while manufacturing efficiencies should limit cost inflation. Against last quarter’s $1.30 billion revenue baseline and historical momentum, expectations imply a supportive environment for EBIT expansion, though seasonality and reimbursement dynamics warrant monitoring.
Surgical Structural Heart
The surgical heart valve therapy business should deliver steady performance as product updates and broadened indications promote share stability in key markets. While growth tends to trail transcatheter therapies, the segment’s margin profile contributes positively to overall profitability when mix improves. Inventory normalization after prior periods of restocking may temper sequential growth, yet year-over-year comparisons remain favorable. With last quarter revenue at $258.00 million, modest year-over-year gains are likely, helped by procedural discipline and incremental product enhancements. Risks include potential delays in elective procedures and competitive pricing exercises in certain regions.
Stock Price Drivers This Quarter
The stock’s near-term reaction will hinge on the degree to which reported revenue aligns with the $1.55 billion consensus and whether adjusted EPS meets or exceeds the $0.62 estimate. Margin commentary will be critical: investors will parse gross margin relative to the 77.77% reference to gauge mix benefits and manufacturing cost control. Any updates on transcatheter therapy adoption, especially signals of sustained double-digit growth, can influence valuation multiples, while guidance cadence for 2026 will frame expectations for procedural volumes and margin sustainability. Management’s articulation of pipeline progress, regulatory timelines, and competitive developments may also affect sentiment.
Analyst Opinions
Recent institutional commentary skews bullish. Citi reiterated a Buy rating with a price target of $101.00, highlighting continued confidence in transcatheter momentum and execution discipline. Barclays maintained a Buy rating with price targets of $104.00 and previously $99.00 across the period, underscoring expectations for steady double-digit growth and healthy margin prospects. Bank of America Securities affirmed a Buy rating, citing positive transcatheter data and supportive market fundamentals, which bolster the earnings trajectory. UBS maintained a Hold rating with a price target of $85.00, reflecting a more balanced stance; however, the majority of recent views are constructive, and the ratio of bullish to neutral/hold commentary favors the bullish camp. The prevailing bullish perspective emphasizes the alignment between forecasted revenue of $1.55 billion, improving EPS at $0.62, and resilient demand in transcatheter therapies, with attention on margin clarity and guidance tone to validate upside potential.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments